Crossmark

Radiotherapy plus a self-gelation powder encapsulating tRF5-GlyGCC inhibitor potentiates natural kill cell immunity to prevent hepatocellular carcinoma recurrence

Crossref DOI link: https://doi.org/10.1186/s12951-025-03133-3

Published Online: 2025-02-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gong, Yihang

Zeng, Fanxin

Zhang, Feng

Liu, Xiaoquan

Li, Zhongheng

Chen, Wenjie

Liu, Haipeng

Li, Xin

Cheng, Yusheng

Zhang, Jian

Feng, Yeqian

Wu, Tiangen

Zhou, Wence

Zhang, Tong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82360550, 82260555)

Natural Science Foundation of Guangdong Province (2022A1515012224)
License Information

Text and Data Mining valid from 2025-02-10

Version of Record valid from 2025-02-10
More Information

Article History

Received: 27 November 2024

Accepted: 17 January 2025

First Online: 10 February 2025

Declarations

:

: This study received the Animal Care and Use Committee of Jennio Biotech Co.,Ltd (IACUC-2024-A037).

: All authors have approved the manuscript and agree for the submission.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below